Clinical Trial Update: Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis

View source ↗

Summary

AbbVie is conducting an oral upadacitinib study to assess change in disease activity in adults with Ulcerative Colitis; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• RINVOQ (Upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Ulcerative Colitis | Status: RECRUITING